{"entity":{"edinet_code":"E22440","sec_code":"3151","name_ja":"株式会社バイタルケーエスケー・ホールディングス","name_en":"VITAL KSK HOLDINGS,INC.","industry":"卸売業","industry_en":"Wholesale Trade"},"names_note":"English company names are as filed: each company's own annual report states its English name on the cover page. For a company that files no annual report, EDINET's filer registry is used instead. The as-filed Japanese name is always returned alongside.","filing":{"doc_id":"S100YDSN","filer_name":"株式会社バイタルケーエスケー・ホールディングス","filer_name_en":"VITAL KSK HOLDINGS,INC.","period_end":"2026-03-31","filed_date":"2026-06-19","sha256":"ce24bf00e3d9630594eac0a6bd280bebcc60e5ce0a7054f7190b2482b5d6cd41","status":"clean"},"basis":{"measurement":"carrying_amount","entity_scope":"holdco_consolidated","share_scope":"both","trust_included":"unknown","as_of":"2026-03-31","period_type":"annual","labels":{"measurement":"Balance-sheet carrying amount. Under Japanese GAAP listed equities are carried at market with the valuation difference in other comprehensive income, so carrying amount and acquisition cost diverge enormously on positions bought decades ago.","entity_scope":"Every disclosing entity in the filing, summed — the reporting company plus each group holder it names.","share_scope":"Listed and unlisted shares together.","trust_included":"The filing does not state whether retirement-benefit-trust shares are included. Never guessed — shares contributed to such a trust leave the holder's balance sheet while the settlor normally keeps the right to instruct the vote.","period_type":"From an annual securities report (有価証券報告書). The policy shareholding table appears only in the annual report."},"not_comparable":"Figures are balance-sheet CARRYING AMOUNT at fiscal year end, from the annual securities report. They are NOT comparable with the acquisition-cost or book-value-reduction figures quoted in press coverage and IR presentations, and NOT comparable with interim (half-year) figures, which this product does not hold. Always state the basis with the number, and use check_claim before setting one of our figures against a published one."},"basis_note":"The basis every yen figure on this response is on. entity_scope is read from the filing's own disclosing entities, not assumed: scale_entities and flows each carry their own entity_scope and share_scope, and a figure quoted for one entity is not the group figure.","holdings":[{"holder_table":"second_largest","held_name_raw":"大塚ホールディングス㈱","held_name_en":"Otsuka Holdings Co., Ltd.","held_sec_code":"4578","match_status":"matched","shares":1464000,"book_value_yen":16118000000,"prior_shares":1464000,"prior_book_value_yen":11305000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"無(注３)","pct_outstanding":0.2772037324187438,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":13.577969285720304,"pct_of_holder_assets":5.027950388061192,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":["3","3"],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"大塚ホールディングス㈱","held_name_en":"Otsuka Holdings Co., Ltd.","held_sec_code":"4578","match_status":"matched","shares":1264000,"book_value_yen":13916000000,"prior_shares":1264000,"prior_book_value_yen":9799000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"無(注３)","pct_outstanding":0.2393343700664564,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":11.722981795513324,"pct_of_holder_assets":4.3410446457537875,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":["3","3"],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"参天製薬㈱","held_name_en":"SANTEN PHARMACEUTICAL CO., LTD.","held_sec_code":"4536","match_status":"matched","shares":837790,"book_value_yen":1495000000,"prior_shares":937790,"prior_book_value_yen":1329000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"有","pct_outstanding":0.26041999040531427,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.2594034050224503,"pct_of_holder_assets":0.46635971151206607,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"第一三共㈱","held_name_en":"DAIICHI SANKYO COMPANY, LIMITED","held_sec_code":"4568","match_status":"matched","shares":385974,"book_value_yen":1067000000,"prior_shares":385974,"prior_book_value_yen":1355000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"無","pct_outstanding":0.02104745713752296,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.8988517947551534,"pct_of_holder_assets":0.3328466971126251,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"エーザイ㈱","held_name_en":"Eisai Co., Ltd.","held_sec_code":"4523","match_status":"matched","shares":206012,"book_value_yen":1003000000,"prior_shares":206012,"prior_book_value_yen":853000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"無","pct_outstanding":0.07302439341629294,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.8449375352759315,"pct_of_holder_assets":0.3128821342117741,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"小野薬品工業㈱","held_name_en":"ONO　PHARMACEUTICAL　CO.,　LTD.","held_sec_code":"4528","match_status":"matched","shares":387810,"book_value_yen":973000000,"prior_shares":580810,"prior_book_value_yen":930000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"有","pct_outstanding":0.08107994531530777,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.8196652261450462,"pct_of_holder_assets":0.3035237453520002,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"second_largest","held_name_raw":"㈱七十七銀行","held_name_en":"The 77 Bank，Ltd.","held_sec_code":"8341","match_status":"matched","shares":64000,"book_value_yen":586000000,"prior_shares":64000,"prior_book_value_yen":304000000,"purpose_ja":"①主要取引金融機関であり、資金調達や営業情報の提供及び良好な取引関係を維持・強化するため　②該当なし　③ＡがＢを下回っております　④該当なし","reciprocal":"有","pct_outstanding":0.08552919976234642,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.493652438356626,"pct_of_holder_assets":0.18280052906091687,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"second_largest","held_name_raw":"㈱ほくやく・竹山ホールディングス","held_name_en":"HOKUYAKU TAKEYAMA Holdings,Inc.","held_sec_code":"3055","match_status":"matched","shares":457781,"book_value_yen":421000000,"prior_shares":457781,"prior_book_value_yen":406000000,"purpose_ja":"①取引関係の維持・強化及び同業者としての情報収集のため　②業務提携契約締結のため　③ＡがＢを下回っております　④該当なし","reciprocal":"無(注４)","pct_outstanding":2.2269728840933634,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.3546547381367569,"pct_of_holder_assets":0.13132939033216043,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"日本新薬㈱","held_name_en":"Nippon Shinyaku Co., Ltd.","held_sec_code":"4516","match_status":"matched","shares":79279,"book_value_yen":405000000,"prior_shares":79279,"prior_book_value_yen":301000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"有","pct_outstanding":0.11762291185541149,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.3411761732669514,"pct_of_holder_assets":0.12633824960694767,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"second_largest","held_name_raw":"カメイ㈱","held_name_en":"KAMEI CORPORATION","held_sec_code":"8037","match_status":"matched","shares":94100,"book_value_yen":308000000,"prior_shares":94100,"prior_book_value_yen":186000000,"purpose_ja":"①取引関係の維持・強化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"有","pct_outstanding":0.30752268126836213,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.25946237374375564,"pct_of_holder_assets":0.09607945896034539,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"サンバイオ㈱","held_name_en":"SanBio Company Limited","held_sec_code":"4592","match_status":"matched","shares":157700,"book_value_yen":280000000,"prior_shares":157700,"prior_book_value_yen":259000000,"purpose_ja":"①取引関係の維持・強化のため　②資本業務提携契約締結のため　③ＡがＢを下回っております　④該当なし","reciprocal":"無","pct_outstanding":0.20209442356384583,"pct_unavailable":null,"pct_basis_period_end":"2026-01-31","pct_share_classes":1,"pct_of_holder_equity":0.23587488522159603,"pct_of_holder_assets":0.08734496269122308,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"second_largest","held_name_raw":"サンバイオ㈱","held_name_en":"SanBio Company Limited","held_sec_code":"4592","match_status":"matched","shares":157700,"book_value_yen":280000000,"prior_shares":157700,"prior_book_value_yen":259000000,"purpose_ja":"①取引関係の維持・強化のため　②資本業務提携契約締結のため　③ＡがＢを下回っております　④該当なし","reciprocal":"無","pct_outstanding":0.20209442356384583,"pct_unavailable":null,"pct_basis_period_end":"2026-01-31","pct_share_classes":1,"pct_of_holder_equity":0.23587488522159603,"pct_of_holder_assets":0.08734496269122308,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"㈱ツムラ","held_name_en":"TSUMURA & CO.","held_sec_code":"4540","match_status":"matched","shares":72200,"book_value_yen":270000000,"prior_shares":72200,"prior_book_value_yen":311000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"無","pct_outstanding":0.09589859252478175,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.2274507821779676,"pct_of_holder_assets":0.08422549973796511,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"明治ホールディングス㈱","held_name_en":"Meiji Holdings Co.,Ltd.","held_sec_code":"2269","match_status":"matched","shares":64852,"book_value_yen":250000000,"prior_shares":64852,"prior_book_value_yen":210000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"無","pct_outstanding":0.023921623595547063,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.21060257609071073,"pct_of_holder_assets":0.07798657383144918,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"住友ファーマ㈱","held_name_en":"Sumitomo Pharma Co., Ltd.","held_sec_code":"4506","match_status":"matched","shares":120378,"book_value_yen":249000000,"prior_shares":120378,"prior_book_value_yen":87000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"有","pct_outstanding":0.030299853164341146,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.2097601657863479,"pct_of_holder_assets":0.07767462753612338,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"second_largest","held_name_raw":"キッセイ薬品工業㈱","held_name_en":"KISSEI PHARMACEUTICAL CO., LTD.","held_sec_code":"4547","match_status":"matched","shares":43696,"book_value_yen":203000000,"prior_shares":43696,"prior_book_value_yen":168000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"有","pct_outstanding":0.10541327414531741,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.17100929178565713,"pct_of_holder_assets":0.06332509795113674,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"second_largest","held_name_raw":"ファーマライズホールディングス㈱","held_name_en":"Ｐｈａｒｍａｒｉｓｅ　Ｈｏｌｄｉｎｇｓ　Ｃｏｒｐｏｒａｔｉｏｎ","held_sec_code":"2796","match_status":"matched","shares":396000,"book_value_yen":203000000,"prior_shares":396000,"prior_book_value_yen":191000000,"purpose_ja":"①株主間契約締結のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"無","pct_outstanding":3.442705597987095,"pct_unavailable":null,"pct_basis_period_end":"2026-05-31","pct_share_classes":1,"pct_of_holder_equity":0.17100929178565713,"pct_of_holder_assets":0.06332509795113674,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"second_largest","held_name_raw":"あすか製薬ホールディングス㈱","held_name_en":"ASKA Pharmaceutical Holdings Co., Ltd.","held_sec_code":"4886","match_status":"matched","shares":46000,"book_value_yen":108000000,"prior_shares":46000,"prior_book_value_yen":105000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"無(注５)","pct_outstanding":0.16198210316083778,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.09098031287118705,"pct_of_holder_assets":0.03369019989518605,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":["4","5"],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"キッセイ薬品工業㈱","held_name_en":"KISSEI PHARMACEUTICAL CO., LTD.","held_sec_code":"4547","match_status":"matched","shares":22145,"book_value_yen":102000000,"prior_shares":22145,"prior_book_value_yen":85000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"有","pct_outstanding":0.05342312696695474,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.08592585104500998,"pct_of_holder_assets":0.03181852212323127,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"旭化成㈱","held_name_en":"ASAHI KASEI CORPORATION","held_sec_code":"3407","match_status":"matched","shares":46517,"book_value_yen":70000000,"prior_shares":46517,"prior_book_value_yen":48000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"無","pct_outstanding":0.0034256306953807467,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.058968721305399006,"pct_of_holder_assets":0.02183624067280577,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"扶桑薬品工業㈱","held_name_en":"Fuso Pharmaceutical Industries, Ltd.","held_sec_code":"4538","match_status":"matched","shares":18297,"book_value_yen":43000000,"prior_shares":18297,"prior_book_value_yen":44000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"無","pct_outstanding":0.21432414333303385,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.036223643087602245,"pct_of_holder_assets":0.01341369069900926,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"持田製薬㈱","held_name_en":"Mochida Pharmaceutical Co.,Ltd.","held_sec_code":"4534","match_status":"matched","shares":8400,"book_value_yen":29000000,"prior_shares":8400,"prior_book_value_yen":26000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"有","pct_outstanding":0.023695546083605783,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.024429898826522446,"pct_of_holder_assets":0.009046442564448105,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"日本化薬㈱","held_name_en":"NIPPON KAYAKU CO.,LTD.","held_sec_code":"4272","match_status":"matched","shares":10000,"book_value_yen":17000000,"prior_shares":10000,"prior_book_value_yen":14000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"有","pct_outstanding":0.0067351451322748826,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.01432097517416833,"pct_of_holder_assets":0.005303087020538544,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"サワイグループホールディングス㈱","held_name_en":"SAWAI GROUP HOLDINGS Co., Ltd.","held_sec_code":"4887","match_status":"matched","shares":6000,"book_value_yen":13000000,"prior_shares":6000,"prior_book_value_yen":11000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"無","pct_outstanding":0.005195451275036046,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.010951333956716958,"pct_of_holder_assets":0.004055301839235357,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"日本ケミファ㈱","held_name_en":"NIPPON CHEMIPHAR CO., LTD.","held_sec_code":"4539","match_status":"matched","shares":5125,"book_value_yen":9000000,"prior_shares":5125,"prior_book_value_yen":7000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"無","pct_outstanding":0.140367887114091,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.007581692739265586,"pct_of_holder_assets":0.0028075166579321705,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"科研製薬㈱","held_name_en":"KAKEN PHARMACEUTICAL CO., LTD.","held_sec_code":"4521","match_status":"matched","shares":2000,"book_value_yen":8000000,"prior_shares":2000,"prior_book_value_yen":8000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"有","pct_outstanding":0.0052537522955613935,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.006739282434902744,"pct_of_holder_assets":0.0024955703626063737,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"ニプロ㈱","held_name_en":"NIPRO CORPORATION","held_sec_code":"8086","match_status":"matched","shares":4100,"book_value_yen":6000000,"prior_shares":4100,"prior_book_value_yen":5000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"無","pct_outstanding":0.0025046568443270064,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.005054461826177058,"pct_of_holder_assets":0.0018716777719547802,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"あすか製薬ホールディングス㈱","held_name_en":"ASKA Pharmaceutical Holdings Co., Ltd.","held_sec_code":"4886","match_status":"matched","shares":2662,"book_value_yen":6000000,"prior_shares":2662,"prior_book_value_yen":6000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"無(注４)","pct_outstanding":0.009373833882916308,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.005054461826177058,"pct_of_holder_assets":0.0018716777719547802,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":["4","5"],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"わかもと製薬㈱","held_name_en":"WAKAMOTO PHARMACEUTICAL CO.,LTD.","held_sec_code":"4512","match_status":"matched","shares":5001,"book_value_yen":1000000,"prior_shares":5001,"prior_book_value_yen":1000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"有","pct_outstanding":0.014409643310184067,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.000842410304362843,"pct_of_holder_assets":0.0003119462953257967,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"second_largest","held_name_raw":"エーザイ㈱","held_name_en":"Eisai Co., Ltd.","held_sec_code":"4523","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":50275,"prior_book_value_yen":208000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③当事業年度中に売却したため、保有効果は検証しておりません　④該当なし","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"second_largest","held_name_raw":"㈱ツムラ","held_name_en":"TSUMURA & CO.","held_sec_code":"4540","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":23400,"prior_book_value_yen":100000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③当事業年度中に売却したため、保有効果は検証しておりません　④該当なし","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"㈱ケアネット","held_name_en":"CareNet,Inc.","held_sec_code":null,"match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":1095600,"prior_book_value_yen":758000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③当事業年度中に売却したため、保有効果の検証はしておりません　④該当なし","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2024-12-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"second_largest","held_name_raw":"㈱ケアネット","held_name_en":"CareNet,Inc.","held_sec_code":null,"match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":1043600,"prior_book_value_yen":722000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③当事業年度中に売却したため、保有効果は検証しておりません　④該当なし","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2024-12-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"杏林製薬㈱","held_name_en":"KYORIN Pharmaceutical Co., Ltd.","held_sec_code":"4569","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":50000,"prior_book_value_yen":75000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③当事業年度中に売却したため、保有効果の検証はしておりません　④該当なし","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"second_largest","held_name_raw":"杏林製薬㈱","held_name_en":"KYORIN Pharmaceutical Co., Ltd.","held_sec_code":"4569","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":185000,"prior_book_value_yen":277000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③当事業年度中に売却したため、保有効果は検証しておりません　④該当なし","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"second_largest","held_name_raw":"住友ファーマ㈱","held_name_en":"Sumitomo Pharma Co., Ltd.","held_sec_code":"4506","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":43345,"prior_book_value_yen":31000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③当事業年度中に売却したため、保有効果は検証しておりません　④該当なし","reciprocal":"有","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"東邦ホールディングス㈱","held_name_en":"TOHO HOLDINGS CO.,LTD.","held_sec_code":"8129","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":250000,"prior_book_value_yen":1115000000,"purpose_ja":"①同業者としての情報収集のため　②該当なし　③当事業年度中に売却したため、保有効果の検証はしておりません　④該当なし","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"鳥居薬品㈱","held_name_en":"TORII PHARMACEUTICAL CO., LTD.","held_sec_code":null,"match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":55956,"prior_book_value_yen":256000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③当事業年度中に売却したため、保有効果の検証はしておりません　④該当なし","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2024-12-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"second_largest","held_name_raw":"バイエル薬品㈱","held_name_en":null,"held_sec_code":null,"match_status":"unmatched","shares":null,"book_value_yen":null,"prior_shares":5000,"prior_book_value_yen":17000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③当事業年度中に売却したため、保有効果は検証しておりません　④該当なし","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false}],"holders":[{"holder_name":"田辺三菱製薬株式会社","holder_name_en":"Mitsubishi Tanabe Pharma Corporation","holder_sec_code":"4508","doc_id":"S100G3TB","period_end":"2019-03-31","holder_table":"reporting","shares":1455296,"book_value_yen":1589000000,"prior_shares":1455296,"prior_book_value_yen":1523000000,"purpose_ja":null,"reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":0.17702684034384875,"pct_of_holder_assets":0.15043274264735118,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":897604000000,"holder_total_assets_yen":1056286000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"塩野義製薬株式会社","holder_name_en":"Shionogi & Co., Ltd.","holder_sec_code":"4507","doc_id":"S100Z43Z","period_end":"2026-03-31","holder_table":"reporting","shares":475000,"book_value_yen":695000000,"prior_shares":475000,"prior_book_value_yen":597000000,"purpose_ja":"同社グループは当社の取引先の一つであるため、医薬品販売等における取引関係維持・強化のために株式を保有しております。2026年５月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しております。","reciprocal":"無","pct_outstanding":0.9798445764344368,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.04124102859279083,"pct_of_holder_assets":0.026970704769740034,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1685215000000,"holder_total_assets_yen":2576870000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社七十七銀行","holder_name_en":"The 77 Bank，Ltd.","holder_sec_code":"8341","doc_id":"S100YAM0","period_end":"2026-03-31","holder_table":"reporting","shares":438700,"book_value_yen":642000000,"prior_shares":438700,"prior_book_value_yen":551000000,"purpose_ja":"当行が営業基盤とする地域に営業・製造拠点を有し、地域経済の成長・活性化等に貢献する企業との総合的な取引関係の維持・強化による取引先および当行の企業価値向上","reciprocal":"無(注３)","pct_outstanding":0.9049638224879735,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.09278743871982241,"pct_of_holder_assets":0.006153665068279323,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":691904000000,"holder_total_assets_yen":10432807000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"大塚ホールディングス株式会社","holder_name_en":"Otsuka Holdings Co., Ltd.","holder_sec_code":"4578","doc_id":"S100XUA7","period_end":"2025-12-31","holder_table":"largest","shares":268500,"book_value_yen":367000000,"prior_shares":268500,"prior_book_value_yen":335000000,"purpose_ja":"医薬品販売等に係る事業上の関係の維持・強化を目的として保有しています。これにより、大塚製薬㈱の事業基盤の安定化に資する協力関係の構築を図っています。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"有","pct_outstanding":0.5538700395213606,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.012098459704547043,"pct_of_holder_assets":0.008743170440365145,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"大正製薬ホールディングス株式会社","holder_name_en":"TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.","holder_sec_code":"4581","doc_id":"S100R80T","period_end":"2023-03-31","holder_table":"reporting","shares":372460,"book_value_yen":333000000,"prior_shares":372460,"prior_book_value_yen":273000000,"purpose_ja":"当社医薬事業における販売取引関係の維持・強化のために保有しています。","reciprocal":"有 ※２","pct_outstanding":0.7176079007076971,"pct_unavailable":null,"pct_basis_period_end":"2023-03-31","pct_share_classes":1,"pct_of_holder_equity":0.041144483859130186,"pct_of_holder_assets":0.0353694675461237,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":809343000000,"holder_total_assets_yen":941490000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"キッセイ薬品工業株式会社","holder_name_en":"KISSEI PHARMACEUTICAL CO., LTD.","holder_sec_code":"4547","doc_id":"S100YFN3","period_end":"2026-03-31","holder_table":"reporting","shares":160777,"book_value_yen":235000000,"prior_shares":160777,"prior_book_value_yen":202000000,"purpose_ja":"同社は医薬品事業における取引先の一つであるため、取引関係維持・強化のために株式を保有しています。具体的には、医療用医薬品の販売先です。2026年４月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しています。","reciprocal":"有","pct_outstanding":0.3316557294008409,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.10149609563955497,"pct_of_holder_assets":0.08542782984230386,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":231536000000,"holder_total_assets_yen":275086000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"参天製薬株式会社","holder_name_en":"SANTEN PHARMACEUTICAL CO., LTD.","holder_sec_code":"4536","doc_id":"S100YDH1","period_end":"2026-03-31","holder_table":"reporting","shares":128474,"book_value_yen":188000000,"prior_shares":128474,"prior_book_value_yen":162000000,"purpose_ja":"当社医薬品等の販売契約があり、眼科領域における事業関係の強化を図ることを目的に保有しています。（注）","reciprocal":"有","pct_outstanding":0.2650201097112375,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0633020078184714,"pct_of_holder_assets":0.04444097741783738,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":296989000000,"holder_total_assets_yen":423033000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"カメイ株式会社","holder_name_en":"KAMEI CORPORATION","holder_sec_code":"8037","doc_id":"S100YKU0","period_end":"2026-03-31","holder_table":"reporting","shares":100800,"book_value_yen":147000000,"prior_shares":100800,"prior_book_value_yen":126000000,"purpose_ja":"ファーマシー事業において、主要な仕入先として、取引関係の構築・強化を目的として保有しております。","reciprocal":"無","pct_outstanding":0.20793333327282362,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.08242312781752528,"pct_of_holder_assets":0.04440269315926672,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":178348000000,"holder_total_assets_yen":331061000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"持田製薬株式会社","holder_name_en":"Mochida Pharmaceutical Co.,Ltd.","holder_sec_code":"4534","doc_id":"S100YI28","period_end":"2026-03-31","holder_table":"reporting","shares":99600,"book_value_yen":145000000,"prior_shares":99600,"prior_book_value_yen":125000000,"purpose_ja":"取引関係の維持・強化のため、保有しております。保有効果を定量的に量りかねるため、取引関係への影響を含む現在及び将来の意義を総合的に判断のうえ、保有の適否を取締役会において、検証しました。なお、同社子会社と医薬品販売等の重要な取引を行っております。","reciprocal":"無(注)","pct_outstanding":0.20545793644814717,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.10333081538702735,"pct_of_holder_assets":0.07935639229422066,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":140326000000,"holder_total_assets_yen":182720000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"あすか製薬ホールディングス株式会社","holder_name_en":"ASKA Pharmaceutical Holdings Co., Ltd.","holder_sec_code":"4886","doc_id":"S100YEAY","period_end":"2026-03-31","holder_table":"largest","shares":93460,"book_value_yen":136000000,"prior_shares":93460,"prior_book_value_yen":117000000,"purpose_ja":"医薬品事業等における特約店であり、中長期的な取引関係の維持と強化を図るため","reciprocal":"有","pct_outstanding":0.19279215602855254,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.17703953449016518,"pct_of_holder_assets":0.12101905160216767,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":76819000000,"holder_total_assets_yen":112379000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"日本新薬株式会社","holder_name_en":"Nippon Shinyaku Co., Ltd.","holder_sec_code":"4516","doc_id":"S100YGRG","period_end":"2026-03-31","holder_table":"reporting","shares":76734,"book_value_yen":112000000,"prior_shares":76734,"prior_book_value_yen":96000000,"purpose_ja":"医薬品事業の販売取引関係の維持・強化を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"有","pct_outstanding":0.15828924995393698,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.03841523438437872,"pct_of_holder_assets":0.03233639085457574,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"日医工株式会社","holder_name_en":"Nichi-Iko Pharmaceutical Co., Ltd.","holder_sec_code":"4541","doc_id":"S100OLZH","period_end":"2022-03-31","holder_table":"reporting","shares":102425,"book_value_yen":75000000,"prior_shares":102425,"prior_book_value_yen":80000000,"purpose_ja":"(保有目的)当社の販売先である医薬品卸であり、販売協力関係構築を目的として保有しております。","reciprocal":"有（注２）","pct_outstanding":0.1919566697619621,"pct_unavailable":null,"pct_basis_period_end":"2022-03-31","pct_share_classes":1,"pct_of_holder_equity":0.5599522174107809,"pct_of_holder_assets":0.028784267670661924,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":13394000000,"holder_total_assets_yen":260559000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社安藤・間","holder_name_en":"HAZAMA ANDO CORPORATION","holder_sec_code":"1719","doc_id":"S100YHJP","period_end":"2026-03-31","holder_table":"reporting","shares":50050,"book_value_yen":73000000,"prior_shares":50050,"prior_book_value_yen":62000000,"purpose_ja":"土木・建築事業における工事契約等の安定的な取引関係を維持・強化するため保有しています。","reciprocal":"無","pct_outstanding":0.10324467589588118,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.034864839048619735,"pct_of_holder_assets":0.01773674299945332,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":209380000000,"holder_total_assets_yen":411575000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"鳥居薬品株式会社","holder_name_en":"TORII PHARMACEUTICAL CO., LTD.","holder_sec_code":"4551","doc_id":"S100VH2F","period_end":"2024-12-31","holder_table":"reporting","shares":44058,"book_value_yen":55000000,"prior_shares":44058,"prior_book_value_yen":45000000,"purpose_ja":"医薬品の販売等における円滑な取引関係を維持するために取得後、継続保有（注）２","reciprocal":"無（注）３","pct_outstanding":0.09106678983633608,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.045255198176626925,"pct_of_holder_assets":0.03910026730364557,"holder_equity_basis":"parent_only","holder_equity_yen":121533000000,"holder_total_assets_yen":140664000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"日本化薬株式会社","holder_name_en":"NIPPON KAYAKU CO.,LTD.","holder_sec_code":"4272","doc_id":"S100YD4R","period_end":"2026-03-31","holder_table":"reporting","shares":34028,"book_value_yen":49000000,"prior_shares":34028,"prior_book_value_yen":42000000,"purpose_ja":"（保有目的）ライフサイエンス事業領域における販売先として関係の維持、強化を図るため（定量的な保有効果）　（注）1 ","reciprocal":"有","pct_outstanding":0.07019400262507582,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.017493502413389313,"pct_of_holder_assets":0.012288832711367922,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":280104000000,"holder_total_assets_yen":398736000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社ユアテック","holder_name_en":"YURTEC CORPORATION","holder_sec_code":"1934","doc_id":"S100YHQP","period_end":"2026-03-31","holder_table":"reporting","shares":30000,"book_value_yen":43000000,"prior_shares":30000,"prior_book_value_yen":37000000,"purpose_ja":"設備工事を請け負っている主要取引先の一つであり、中長期的な工事受注獲得による収益向上をはかるため継続して保有している。","reciprocal":"無","pct_outstanding":0.061884920616911795,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.027678364530497695,"pct_of_holder_assets":0.018781557384209516,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":155356000000,"holder_total_assets_yen":228948000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社福田組","holder_name_en":"FUKUDA CORPORATION","holder_sec_code":"1899","doc_id":"S100XT0V","period_end":"2025-12-31","holder_table":"reporting","shares":29242,"book_value_yen":40000000,"prior_shares":28957,"prior_book_value_yen":36000000,"purpose_ja":"定量的な保有効果については営業秘密等の観点から記載が困難ですが、建設事業において、工事請負等の取引を行っており、信頼関係の構築・維持強化の必要性や事業上の取引状況等に基づく保有意義、同社との取引関係等による経済合理性について取締役会で定期的に検証等を行い、保有の合理性があると判断しております。また株式数が増加した理由については、取引先持株会を通じた株式取得のため増加しております。","reciprocal":"無","pct_outstanding":0.06032129495599116,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.04436262005634053,"pct_of_holder_assets":0.027123057311020098,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":90166000000,"holder_total_assets_yen":147476000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社メディパルホールディングス","holder_name_en":"MEDIPAL HOLDINGS CORPORATION","holder_sec_code":"7459","doc_id":"S100YI1C","period_end":"2026-03-31","holder_table":"reporting","shares":11361,"book_value_yen":16000000,"prior_shares":11361,"prior_book_value_yen":14000000,"purpose_ja":"・事業の円滑な取引関係維持のため保有しております。 ・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.023435819437624496,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0020115690364207145,"pct_of_holder_assets":0.0008324653148123675,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"久光製薬株式会社","holder_name_en":"HISAMITSU PHARMACEUTICAL CO.,INC.","holder_sec_code":"4530","doc_id":"S100VT69","period_end":"2025-02-28","holder_table":"reporting","shares":13200,"book_value_yen":15000000,"prior_shares":13200,"prior_book_value_yen":17000000,"purpose_ja":"医薬品事業の販売先であり、取引関係維持・強化を図るため。","reciprocal":"無","pct_outstanding":0.02728407158381307,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.005368512599899072,"pct_of_holder_assets":0.004372311028717339,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"わかもと製薬株式会社","holder_name_en":"WAKAMOTO PHARMACEUTICAL CO.,LTD.","holder_sec_code":"4512","doc_id":"S100YDBU","period_end":"2026-03-31","holder_table":"reporting","shares":6615,"book_value_yen":9690000,"prior_shares":6615,"prior_book_value_yen":8321000,"purpose_ja":"同社傘下の企業が医薬事業における顧客であり、取引関係の維持・強化のため保有しています。","reciprocal":"有","pct_outstanding":0.013645624996029051,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.08069229828236991,"pct_of_holder_assets":0.058728671537449345,"holder_equity_basis":"parent_only","holder_equity_yen":12008581000,"holder_total_assets_yen":16499607000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"科研製薬株式会社","holder_name_en":"KAKEN PHARMACEUTICAL CO., LTD.","holder_sec_code":"4521","doc_id":"S100YK2Q","period_end":"2026-03-31","holder_table":"reporting","shares":6615,"book_value_yen":9000000,"prior_shares":6615,"prior_book_value_yen":8000000,"purpose_ja":"医薬品販売に係る取引円滑化のため、当社の持続成長や企業価値向上から総合的に判断し保有しております。","reciprocal":"有","pct_outstanding":0.013645624996029051,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0060967761602503745,"pct_of_holder_assets":0.005050023286218486,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":147619000000,"holder_total_assets_yen":178217000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"川本産業株式会社","holder_name_en":"KAWAMOTO CORPORATION","holder_sec_code":"3604","doc_id":"S100TT3D","period_end":"2024-03-31","holder_table":"reporting","shares":3307,"book_value_yen":4153000,"prior_shares":3307,"prior_book_value_yen":2956000,"purpose_ja":"同社傘下の企業は当社の販売先であり、良好な取引関係の維持、強化を目的として保有しております。","reciprocal":"無","pct_outstanding":0.006574150654325791,"pct_unavailable":null,"pct_basis_period_end":"2024-03-31","pct_share_classes":1,"pct_of_holder_equity":0.05358186303608796,"pct_of_holder_assets":0.021243633943285992,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":7750757000,"holder_total_assets_yen":19549386000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"ゼリア新薬工業株式会社","holder_name_en":"ZERIA PHARMACEUTICAL CO., LTD.","holder_sec_code":"4559","doc_id":"S100YKC2","period_end":"2026-03-31","holder_table":"reporting","shares":1000,"book_value_yen":1465000,"prior_shares":1000,"prior_book_value_yen":1258000,"purpose_ja":"（保有目的）医療用医薬品事業活動の円滑な推進（定量的な保有効果）（注）１","reciprocal":"無","pct_outstanding":0.002062830687230393,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0013489276117563506,"pct_of_holder_assets":0.0008152569398552234,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":108604790000,"holder_total_assets_yen":179697949000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社ミズホメディー","holder_name_en":"MIZUHO MEDY CO.,LTD.","holder_sec_code":"4595","doc_id":"S100XTF0","period_end":"2025-12-31","holder_table":"reporting","shares":1000,"book_value_yen":1000000,"prior_shares":1000,"prior_book_value_yen":1000000,"purpose_ja":"体外診断用医薬品事業における機器・試薬の販売先として、取引関係の維持・強化のため保有しております。定量的な保有効果につきましては、測定が困難であるため記載しておりませんが、資本コストを踏まえ、取引状況等を検証した結果、保有の合理性はあると判断いたしました。","reciprocal":"無","pct_outstanding":0.002062830687230393,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.005352172982230786,"pct_of_holder_assets":0.004469273743016759,"holder_equity_basis":"parent_only","holder_equity_yen":18684000000,"holder_total_assets_yen":22375000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"住友ファーマ株式会社","holder_name_en":"Sumitomo Pharma Co., Ltd.","holder_sec_code":"4506","doc_id":"S100YH3M","period_end":"2026-03-31","holder_table":"reporting","shares":null,"book_value_yen":null,"prior_shares":399900,"prior_book_value_yen":503000000,"purpose_ja":"重要な特約店として同社と良好な関係を維持・強化していくことの重要性等に加え、資本コストを勘案した配当・取引額等の定量的な評価の実施を通じて、総合的に判断し保有していました。","reciprocal":"無※","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":292467000000,"holder_total_assets_yen":804571000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"杏林製薬株式会社","holder_name_en":"KYORIN Pharmaceutical Co., Ltd.","holder_sec_code":"4569","doc_id":"S100YDHG","period_end":"2026-03-31","holder_table":"reporting","shares":null,"book_value_yen":null,"prior_shares":603200,"prior_book_value_yen":758000000,"purpose_ja":"同社株式は、当事業年度中に全て売却しております","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":142425000000,"holder_total_assets_yen":195455000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"エーザイ株式会社","holder_name_en":"Eisai Co., Ltd.","holder_sec_code":"4523","doc_id":"S100YB05","period_end":"2026-03-31","holder_table":"reporting","shares":null,"book_value_yen":null,"prior_shares":298854,"prior_book_value_yen":376000000,"purpose_ja":"・医療用医薬品販売事業等における取引関係の強化のため保有していましたが、当事業年度に全株式を売却しています。","reciprocal":"有","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":898992000000,"holder_total_assets_yen":1449113000000,"implausible":false,"reciprocal_held_both_ways":true}],"reclassified":[],"reclassified_note":"As filed, from the annual report's 保有目的を変更した投資株式 table. direction=to_pure means the filer moved the holding from a policy shareholding to 純投資目的 (pure investment); the shares are not necessarily sold, and the position leaves the named policy table in the year of the change. direction=to_policy is the reverse. fy_of_change_ja is the fiscal year the filer states the change took effect, verbatim — some filers list more than one. A filing repeats these rows for several years after the change, so this is a standing disclosure, not a one-year event.","implausible_note":"A row is flagged implausible when its two filed numbers are mutually impossible — book value ÷ shares of ¥1,000,000 or more, which no listed Japanese share reaches. It is a filer tagging error (a value entered at the wrong scale, or a share count in thousands), not an extraction error: the values match the filing's XBRL exactly. Flagged rows are still returned, exactly as filed, but are excluded from the yen aggregates here and counted in excluded_positions / excluded_yen so the exclusion is visible.","notes":[{"holder_table":"largest","note_no":"1","text_ja":"（注）１．当該銘柄の企業との取引により生じた利益や受取配当金などのリターンを「Ａ」、株主資本コスト等から算出した当該銘柄に対する要求利益水準を「Ｂ」とし、両者の比較結果を記載しております。なお、2026年３月期の数値を基に、2026年６月18日の取締役会で保有効果の検証をしております。"},{"holder_table":"largest","note_no":"2","text_ja":"２．「－」は当該銘柄を保有していないことを示しております。"},{"holder_table":"largest","note_no":"3","text_ja":"３．関係会社である大塚製薬㈱、大鵬薬品工業㈱が当社株式を保有しております。"},{"holder_table":"largest","note_no":"4","text_ja":"４．関係会社である あすか製薬㈱が当社株式を保有しております。"},{"holder_table":"second_largest","note_no":"1","text_ja":"（注）１．当該銘柄の企業との取引により生じた利益や受取配当金などのリターンを「Ａ」、株主資本コスト等から算出した当該銘柄に対する要求利益水準を「Ｂ」とし、両者の比較結果を記載しております。なお、2026年３月期の数値を基に、2026年６月18日の取締役会で保有効果の検証をしております。"},{"holder_table":"second_largest","note_no":"2","text_ja":"２．「－」は当該銘柄を保有していないことを示しております。"},{"holder_table":"second_largest","note_no":"3","text_ja":"３．関係会社である大塚製薬㈱、大鵬薬品工業㈱が当社株式を保有しております。"},{"holder_table":"second_largest","note_no":"4","text_ja":"４．関係会社である㈱ほくやくが当社株式を保有しております。"},{"holder_table":"second_largest","note_no":"5","text_ja":"５．関係会社である あすか製薬㈱が当社株式を保有しております。"}],"notes_note":"The filing's own numbered footnotes to the named policy table, verbatim. The XBRL numbers them (注)1, (注)2 … and gives no link back to a row, so a note is tied to a position only where it names that issuer.","flows":[{"holder_table":"largest","share_class":"listed","issues_increased":null,"acquisition_cost_yen":null,"issues_decreased":6,"sale_proceeds_yen":3470000000,"entity_scope":"largest_holding_company","share_scope":"listed"},{"holder_table":"largest","share_class":"unlisted","issues_increased":null,"acquisition_cost_yen":null,"issues_decreased":1,"sale_proceeds_yen":97000000,"entity_scope":"largest_holding_company","share_scope":"unlisted"},{"holder_table":"second_largest","share_class":"listed","issues_increased":null,"acquisition_cost_yen":null,"issues_decreased":6,"sale_proceeds_yen":1907000000,"entity_scope":"second_largest_holding_company","share_scope":"listed"},{"holder_table":"second_largest","share_class":"unlisted","issues_increased":null,"acquisition_cost_yen":null,"issues_decreased":null,"sale_proceeds_yen":null,"entity_scope":"second_largest_holding_company","share_scope":"unlisted"}],"flows_note":"The filer's own tally, as filed, of how many issues increased or decreased during the year and the yen involved — acquisition cost for increases, sale proceeds for decreases. Read against the reclassification table this separates what was actually sold from what merely changed category. Counts are as filed and are not corrected for filer tagging errors.","no_reduction_measure":"This product holds sale proceeds (売却価額), as filed, for one fiscal year. It does NOT hold a book-value-reduction measure. The two are different measures and must never be presented as equivalent.","scale":{"policy_total_yen":38942000000,"listed_yen":38479000000,"unlisted_yen":463000000,"listed_issues":38,"unlisted_issues":36,"equity_yen":118707000000,"equity_basis":"jgaap_consolidated","total_assets_yen":320568000000,"assets_basis":"jgaap_consolidated","pct_of_equity":32.80514207249783,"pct_of_assets":12.147812632577175,"equity_basis_label":"Consolidated net assets (Japanese GAAP)","assets_basis_label":"Consolidated net assets (Japanese GAAP)","equity_calc":"total policy shareholdings ÷ shareholders' equity × 100, both as filed in this annual securities report","assets_calc":"total policy shareholdings ÷ total assets × 100, both as filed in this annual securities report"},"scale_entities":[{"holder_table":"reporting","share_class":"unlisted","book_value_yen":109000000,"issue_count":3,"holder_table_label":"The filer itself","entity_scope":"parent_only","share_scope":"unlisted"},{"holder_table":"largest","share_class":"listed","book_value_yen":20222000000,"issue_count":21,"holder_table_label":"Largest holder in the group","entity_scope":"largest_holding_company","share_scope":"listed"},{"holder_table":"largest","share_class":"unlisted","book_value_yen":32000000,"issue_count":7,"holder_table_label":"Largest holder in the group","entity_scope":"largest_holding_company","share_scope":"unlisted"},{"holder_table":"second_largest","share_class":"listed","book_value_yen":18257000000,"issue_count":17,"holder_table_label":"Second largest holder in the group","entity_scope":"second_largest_holding_company","share_scope":"listed"},{"holder_table":"second_largest","share_class":"unlisted","book_value_yen":322000000,"issue_count":26,"holder_table_label":"Second largest holder in the group","entity_scope":"second_largest_holding_company","share_scope":"unlisted"}],"scale_history":[{"year":"2022","period_end":"2022-03-31","policy_total_yen":35540000000,"equity_yen":100041000000,"equity_basis":"jgaap_consolidated","pct_of_equity":35.52543457182555,"pct_of_assets":11.353435580274285},{"year":"2023","period_end":"2023-03-31","policy_total_yen":31469000000,"equity_yen":100165000000,"equity_basis":"jgaap_consolidated","pct_of_equity":31.417161683222684,"pct_of_assets":10.584361420172476},{"year":"2024","period_end":"2024-03-31","policy_total_yen":35881000000,"equity_yen":105940000000,"equity_basis":"jgaap_consolidated","pct_of_equity":33.869171228997544,"pct_of_assets":11.309722686267959},{"year":"2025","period_end":"2025-03-31","policy_total_yen":32950000000,"equity_yen":107306000000,"equity_basis":"jgaap_consolidated","pct_of_equity":30.706577451400666,"pct_of_assets":11.004388396465236},{"year":"2026","period_end":"2026-03-31","policy_total_yen":38942000000,"equity_yen":118707000000,"equity_basis":"jgaap_consolidated","pct_of_equity":32.80514207249783,"pct_of_assets":12.147812632577175}],"scale_note":"The policy total is Official (as filed) — the filing's own total carrying amount for the whole policy bucket, listed and unlisted, summed across the entities the filing discloses. It is a floor: holdings at group companies the filing does not name are disclosed nowhere and are not included. The percentages are calculated, not filed, and carry their formula. equity_basis names which figure the denominator is, because filers report under Japanese, IFRS or US accounting standards and an adopter of the latter two stops tagging the Japanese consolidated figure — a parent-only denominator is a different measure and is labelled as one, never silently mixed with a group figure. Percentages are null where equity or total assets is missing or not positive; missing is never shown as zero.","scale_reference":"ISS's Japan proxy voting guidelines recommend a vote against the top executive at a company that allocates 20 percent or more of its net assets to cross-shareholdings, a policy effective from February 2022. ISS counts unilateral holdings, not only mutual ones.","ownership_calc":"shares held ÷ (issuer's issued shares − treasury shares) × 100, both as filed, the denominator taken from the issuer's own annual securities report nearest the holding's fiscal year end","ownership_note":"Derived, not filed. The denominator is the issuer's own reported issued shares less treasury shares, from its annual report nearest this holding's fiscal year end on either side — pct_basis_period_end gives that date, and it can fall after the holding's date where that report is the closer one. For a single-class listed stock this equals the stake's share of market capitalisation. It is null where the issuer files no annual report we hold; where the issuer's share count moves by half or more across the window, because a split or issue makes the share base indeterminate; and where the result would exceed 100%, which is a data fault rather than a stake. It is less exact where the issuer has more than one share class (pct_share_classes > 1), because treasury shares are reported across all classes.","holder_share_calc":"this position's book value ÷ the holder's shareholders' equity (or total assets) × 100, both as filed in the holder's own annual securities report","holder_share_note":"The mirror of pct_outstanding. That sizes a stake against the ISSUER — how much of the issuer this holder owns. pct_of_holder_equity and pct_of_holder_assets size the same position against the HOLDER: how much of its own capital is committed to this one name. Calculated, not filed. Null where the holder's filing gives no usable denominator, never zero. holder_equity_basis says which accounting figure the denominator is, and a parent_only basis is not comparable with a consolidated one. A position CAN legitimately exceed 100% of equity — a holder whose book equity is smaller than one long-held stake is a real and commercially interesting case, not an error — so no ceiling is imposed. Extreme values are worth checking against the filing: where the position's own two filed numbers are mutually impossible the row is marked `implausible`, but that test catches only scale errors visible per share, so it does not catch every bad figure. The book value and share count are returned alongside so the reader can check.","action_calc":"keyword match over the filing's own stated purpose and table footnotes: 株式分割、株式併合、株式交換、株式移転、会社分割、合併、持株会社、商号変更、公開買付、上場廃止","ratio_calc":"current shares ÷ prior shares where that ratio is an exact whole number (or its exact reciprocal) — the signature of a split or a consolidation rather than a trade","history":[{"year":"2022","period_end":"2022-03-31","named_holdings":54,"book_value_yen":34889000000},{"year":"2023","period_end":"2023-03-31","named_holdings":51,"book_value_yen":30790000000},{"year":"2024","period_end":"2024-03-31","named_holdings":49,"book_value_yen":33871000000},{"year":"2025","period_end":"2025-03-31","named_holdings":48,"book_value_yen":32185000000},{"year":"2026","period_end":"2026-03-31","named_holdings":39,"book_value_yen":38439000000}],"history_note":"One point per annual report filed. Each year's book value is as filed; book values are fair-valued at period end, so a change reflects both trading and market moves.","provenance":{"trust":"official","note":"Figures exactly as filed in each company's 有価証券報告書 (annual securities report), EDINET. Raw filings archived with SHA-256; doc_id links to the source filing."}}